Analysis of the therapeutic efficacy of drugs for the treatment of unstable angina pectoris in the context of DRGs payment
Objective To analyse the therapeutic efficacy of drugs for the treatment of unstable angina pectoris in the context of payment by Disease-Related Groups(DRGs).Methods Unstable angina pectoris treatment cases admitted between November 2020 and October 2022 were selected for retrospective analysis,with a total number of 600 cases,and they were divided into the conventional group(300 cases from November 2020 to October 2021)and the study group(300 cases from November 2021 to October 2022).The conventional group was given medication according to the routine pattern of clinical medication,and the study group was given medication based on the DRGs payment background.The two groups were compared in terms of clinical indicators such as symptom disappearance time and chest pain duration;therapeutic indicators such as drug cost and total hospitalisation cost;and therapeutic effects and incidence of irrational drug use.Results Compared with the conventional group,the study group had shorter symptom disappearance time of chest pain,dyspnea,palpitations,etc.,average duration of single chest pain,and hospital stay(P＜0.05);the study group had lower drug costs and total hospital costs(P＜0.05),and the study group had a lower drug-to-patient ratio(P＜0.05);and the study group had higher total effective rate of treatment compared with the conventional group(P＜0.05);compared with the conventional group,the percentage of irrational medication use such as overdose,duplicate medication,usage error,drug selection error,prescription formulation error,etc.,occurring in the study group was lower(P＜0.05).Conclusion Determining the therapeutic drugs for unstable angina pectoris and providing symptomatic treatment in the context of DRGs payment can rapidly improve the clinical symptoms of patients,significantly improve the effectiveness of treatment,and reduce the probability of irrational use of medication,thereby reducing the cost of medicines and the total cost of hospitalisation,and alleviating the economic burden of patients.
NETL
